Nanobiotix Aktie [WKN DE: A1J7EB / ISIN: FR0011341205]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Nanobiotix SA

04.06.19		NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL (GlobeNewswire)
28.05.19		Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare (GlobeNewswire)
09.04.19		Nanobiotix Raises Approximately EUR 29.5 Million in Placement of Ordinary New Shares (Businesswire)
08.04.19		NANOBIOTIX Launches a Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
04.04.19		Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval (GlobeNewswire)
02.04.19		Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer (GlobeNewswire)
26.03.19		Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback (GlobeNewswire)
15.03.19		Nanobiotix 2018 Annual Results (GlobeNewswire)
04.03.19		Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank (GlobeNewswire)
16.01.19		Nanobiotix Plans to Conduct Registered Public Offering in the United States (GlobeNewswire)
07.01.19		Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3 (GlobeNewswire)
19.10.18		NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO (GlobeNewswire)
16.10.18		Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank (GlobeNewswire)
26.09.18		Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual c (GlobeNewswire)
20.09.18		Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 (GlobeNewswire)
04.09.18		NANOBIOTIX half year results for the six months ended June 30, 2018 (GlobeNewswire)
26.07.18		NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment Bank (GlobeNewswire)
21.06.18		NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 (GlobeNewswire)
06.06.18		NANOBIOTIX' Management statement on recent share price variation (GlobeNewswire)
03.05.18		Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers (GlobeNewswire)
17.04.18		AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway (GlobeNewswire)
10.04.18		NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB (GlobeNewswire)
30.03.18		NANOBIOTIX : Nanobiotix 2017 Annual Results (GlobeNewswire)
28.02.18		Nanobiotix 2017 Q4 and Annual Revenues (Businesswire)
22.01.18		Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting (Businesswire)
22.01.18		NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting (GlobeNewswire)
11.01.18		NANOBIOTIX Partners with the Providence Cancer Institute to Run Immunotherapeutic Preclinical Research in Pancreatic Cancers (Businesswire)
11.01.18		NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers (GlobeNewswire)
26.12.17		Nanobiotix: 2017 Review and 2018 Expected Milestones (Businesswire)
26.12.17		NANOBIOTIX : 2017 review and 2018 expected milestones (GlobeNewswire)
26.12.17		NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial (GlobeNewswire)
15.11.17		Nanobiotix revenues for the 3rd quarter of 2017 (Businesswire)
13.11.17		Nanobiotix Presented New Clinical and Pre-Clinical Data Confirming NBTXR3’s Significant Potential Role In Immuno-Oncology at SITC Annual Meeting (Businesswire)
13.11.17		NANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting (GlobeNewswire)
09.11.17		Nanobiotix Provides Update on the Global Development of Its Lead Product NBTXR3 (Businesswire)
09.11.17		NANOBIOTIX provides update on the global development of its lead product NBTXR3 (GlobeNewswire)
31.10.17		NANOBIOTIX Successfully Completes Approximately Eur 27.2 Million Placement of New Shares (Businesswire)
30.10.17		Nanobiotix Launches Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
23.10.17		NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma (GlobeNewswire)
28.09.17		Nanobiotix Plans to Conduct Its First Clinical Trial with NBTXR3 in Combination with Immune Checkpoint Inhibitors in the U.S. (Businesswire)
28.09.17		NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. (GlobeNewswire)
31.08.17		Nanobiotix half year results for the six months ended 30 June 2017 (Businesswire)
31.08.17		NANOBIOTIX half year results for the six months ended 30 June 2017 (GlobeNewswire)
12.07.17		Nanobiotix Revenues for the 2nd Quarter of 2017 (Businesswire)
15.05.17		Nanobiotix revenue for the 1st quarter of 2017 (Businesswire)
28.04.17		Nanobiotix: 2016 Annual Results (Businesswire)
28.11.16		NANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3 (GlobeNewswire)
15.11.16		Nanobiotix Revenue for Q3 2016 (Businesswire)
14.11.16		NANOBIOTIX Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as in Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting (Businesswire)
14.11.16		NANOBIOTIX presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 15:59
Kaufwert:	EUR
	Hinzufügen Speichern